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Abstract
Pharmacogenetic studies have demonstrated significant associations between several candidate
genes (DRD2, DRD3, 5HTR2A and 5HTR2C, COMT and MTHFR) and antipsychotic drug response.
The present study investigates the effect of nine polymorphisms in these genes for an association
with antipsychotic treatment response. 329 Caucasian patients with a non-affective psychotic
disorder using antipsychotics were included. All patients participated in the longitudinal
GROUP-study in The Netherlands. We genotyped 9 SNPs in 6 candidate genes (DRD2: TaqI_A,
-141C; DRD3: Ser9Gly; HTR2A: 102-T/C, His452Tyr; HTR2C: Cys23Ser; COMT: Val158Met;eman, Department of Psychiatry, University Medical Center Groningen, University of Groningen,
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626 J. Vehof et al.MTHFR: 677-C/T) using standard protocols. Polymorphisms were based on previous studies
showing associations with positive symptoms treatment response. The Clinical Global Impression -
Improvement (CGI-I) scale was used to assess improvement in positive psychotic symptoms since
the start of current antipsychotic treatment. Ordinal regression was used for association analyses.
Ninety percent of the patients used second generation antipsychotics, with olanzapine (28%) and ris-
peridone (29%) being themost prescribed drugs. Ser9Gly of the dopamine D3 receptor gene (P value
0.034) and 677-C/T of MTHFR (P value 0.019) were tested statistically significant. Gly-carriers and
T-carriers, respectively, showed more clinical improvement on the CGI-I. The other polymorphisms
did not show a statistically significant association (P valuesN0.10). In conclusion, we replicated two
out of nine of the previously reported associations between polymorphisms and treatment response.
The direction and magnitude of the associations presented here in DRD3 (Ser9Gly) and MTHFR (677-
C/T) are in line with previous association studies in Caucasian patients. These polymorphisms may
be of value for predicting clinical response.
© 2012 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Since their introduction in the 1950s antipsychotic drugs play
a key role in the treatment of psychotic disorders. However,
almost half of patients with schizophrenia display insuffi-
cient response to antipsychotic treatment and many patients
show low compliance as a result (Lacro et al., 2002). In turn,
this may cause clinical deterioration including psychotic
relapse. Factors that influence the variation in response to
antipsychotic drug treatment have not been well elucidated.
Inter-individual and inter-racial variability in response to
drug treatment may possibly reflect genetic heterogeneity
and the presence of modifier genes (Tsuang et al., 1990).
Several genetic association studies have been performed
showing positive associations between response and poly-
morphisms in genes coding for the dopaminergic, serotoner-
gic, and several other systems. In this study we focus on
polymorphisms associated with antipsychotic drug response
(positive or global symptoms) in Caucasian patients only.
Dopamine D2 receptor blockade is a property of all antipsy-
chotics. The polymorphisms Taq1A, located downstream of
the dopamine receptor D2 gene (DRD2), and -141C Ins/Del,
located in the promoter region of DRD2, are linked to D2
receptor density at the level of the striatum (Jonsson et al.,
1999; Laakso et al., 2005; Pohjalainen et al., 1998). Several
studies have associated TaqI_A and -141C with response to
first (FGA) and second generation antipsychotics (SGA)
(Hwang et al., 2005; Lencz et al., 2006; Schafer et al.,
2001). The affinity of certain antipsychotics for the D3 recep-
tor may reflect a part of their action, although affinity for the
D3 receptor may differ among them (Schwartz et al., 2000).
The Ser9Gly polymorphism of DRD3 is an amino-acid substitu-
tion in the N-terminal extracellular part of the receptor and
might influence the membrane expression of this receptor
by modifying its intracellular maturation (Reynolds et al.,
2005). A positive relation between response to SGA and the
presence of the Gly allele was found in three studies (Staddon
et al., 2002; Szekeres et al., 2004; Scharfetter et al., 1999).
Alterations in the serotoninergic system have been impli-
cated in the mechanisms of action of antipsychotics, having
antagonistic properties (particularly SGA) on serotoninergic
receptors, especially the serotonin 2A and 2C receptors. Two
SNPs (His452Tyr and 102-T/C) of the 5HTR2A (serotonin recep-
tor 2A) gene were the subject of several association studies on
the response to clozapine. Results were conflicting (Maselliset al., 1995, 1998; Malhotra et al., 1996; Joober et al., 1999;
Jonsson et al., 1996; Arranz et al., 1995, 1996, 1998a,
1998b). The 102-T/C SNP does not entail amino acid substitu-
tion, but in Caucasian patients it is in complete linkage dis-
equilibrium with variant -1438A/G, which is located in the
gene promoter. The A allele of this polymorphism would in-
crease the in-vitro activity of the promoter (Parsons et al.,
2004). The His452Tyr polymorphism brings about functional
modifications of the receptor, the Tyr variant would decrease
the receptor's ability to activate C and D phospholipases
(Hazelwood and Sanders-Bush, 2004). The serotonin 2C recep-
tor is suggested to play a moderate role in the effect of anti-
psychotics on particularly negative symptoms (Sodhi et al.,
1995; Reynolds et al., 2005; Arranz et al., 2000a; Lieberman
et al., 1998). The Cys23Ser polymorphism of the 5HTR2C (sero-
tonin receptor 2C) gene was associated in one study with
global response on clozapine (Sodhi et al., 1995). The conse-
quences of the involved amino acid substitution are unknown.
COMT (catechol-O-methyltransferase) is involved in the
degradation of dopamine in the prefrontal cortex. The
COMT gene has a relevant Val158Met polymorphism (some-
times referred to as Val158/108Met). The Met allele was
associated with a better response in two studies (Anttila et
al., 2004; Bertolino et al., 2004). The MTHFR (methylenete-
trahydrofolate reductase) enzyme is required for the synthesis
of 5-MTHF, a cosubstrate for the conversion of homocysteine
into methionine. Elevated plasma homocysteine concentra-
tion has been suggested as a risk factor for schizophrenia but
the causality is still unclear. The MTHFR gene has a missense
mutation 677-C/T. Patients possessing a copy of the T allele
showed a better treatment response (Joober et al., 2000a).
In the present study we tested above mentioned nine
polymorphisms for their association with response on posi-
tive symptoms in a sample of Caucasian patients with a psy-
chotic disorder. We focused on polymorphisms associated
with response on positive symptoms because antipsychotics
are mainly effective for treating positive symptoms.2. Experimental procedures
2.1. Sample
A sample of 329 in- and outpatients using antipsychotic medication
was drawn from the participants in the ongoing longitudinal Genetic
Risk and Outcome of Psychosis (GROUP) study. In GROUP, patients
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Netherlands and Belgium. Inclusion criteria for GROUP were: (i) age
range 16 to 50 years, (ii) DSM-IV diagnosis of non-affective psychotic
disorder and (iii) good command of Dutch language. For the present
analysis the following extra inclusion criteria were applied: (iv) use
of antipsychotic medication at the time of assessment for at least
one month and (v) Caucasian ethnicity of Northern European
ancestry. The study was approved by the Ethics Committee of the
University Medical Center Utrecht and by the institutional review
boards of all other participating hospitals. All subjects gave written
informed consent in accordance with the committee's guidelines.
2.2. Genotyping
A total of 9 polymorphisms in 6 candidate genes were selected for
the current study: DRD2 TaqI_A and -141C; DRD3 Ser9Gly; HTR2A:
102-T/C and His452Tyr; HTR2C: Cys23Ser; COMT: Val158Met;
MTHFR: 677-C/T. These polymorphisms were chosen a priori based
on findings in other association studies and determined by Seque-
nom (Hamburg, Germany) using the Sequenom MassARRAY iPLEX
platform at the facilities of the manufacturer. Quality check for
genotyping was performed in the overall GROUP study, which
encompassed exclusion of polymorphisms and individuals based on
missingness and based on departure from Hardy–Weinberg equilibri-
um in a sample of 398 controls without a psychotic disorder.
2.3. Phenotyping
All patients were evaluated by their attending psychiatrist with the
Clinical Global Impression - Improvement (CGI-I) scale at one point
in time. This instrument was used to score the change in positive
symptoms since the start of the current antipsychotic medication
on a seven point scale (1, very much improved; 2, much improved;
3, minimally improved; 4, no change; 5, minimally worse; 6, much
worse; or 7, very much worse). Response was dichotomized for
some of the analyses: improvement was defined as a CGI-I score of
very much improved or much improved. Attending psychiatrists
were blinded to patient's genotype. Other clinical variables that
were measured in this study were DSM-IV diagnosis, duration of ill-
ness, and antipsychotic medication and dose. Haloperidol dose
equivalents were subsequently calculated using power formulas as
outlined by Andreasen et al. (2010). To assess DSM-IV diagnosis one
of the two structured diagnostic instruments was used: the Compre-
hensive Assessment of Symptoms and History (CASH (Andreasen et
al., 1992)) or the SCAN Schedules for Clinical Assessment for Neuro-
psychiatry (SCAN 2.1 (Wing et al., 1990)). All raters were trained
psychologist or psychiatrist, with extensive clinical experience.
They had completed training in the CASH or SCAN. Diagnostic con-
sensus was achieved in the presence of an independent psychiatrist.
Psychiatric diagnosis was established according to the criteria of
DSM-IV. Haloperidol dose equivalents were subsequently calculated
using power formulas as outlined by Andreasen et al. (2010).
2.4. Statistical analysis
Age, duration of illness and haloperidol dose equivalents were com-
pared between patients with and without response and were tested
for statistical significance using a Mann–Whitney test or t-test when
appropriate. We compared response between themost frequently pre-
scribed antipsychotics and between diagnoses and tested differences
for statistical significance using the χ2 test. Ordinal regression (Scott
et al., 1997), with the logit link function, was used to quantify the as-
sociation between the highly skewed CGI-I score on positive symptoms
and polymorphisms, while adjusting for age and gender. Sequential
low prevalent outcome groups were pooled to fulfill the assumptions
of ordinal regression, i.e. high enough cell counts in each genotype/
outcome group (minimum of 1). The null hypothesis of parallel lineswas tested for each polymorphismusing χ2 tests.We considered initial-
ly an additive model with the number of minor alleles as independent
variable for all polymorphisms. When genotype/outcome group cell
counts were too low, a dominant model for the polymorphismwas con-
sidered. Polymorphisms positioned on the X-chromosome were tested
in a dominant model only. All statistical analyses were performed
using SPSS 16.0 for Windows. Since all nine polymorphisms were
based on earlier positive association studies in Caucasian patients,
we refrained from adjusting for the multiple testing. The significance
level of this study was set at 0.05, two-sided. Replication was estab-
lished when the effect was in the same direction as in the original
study and statistically significant.
3. Results
Descriptive statistics of our study sample are presented in
Table 1 according to response on positive symptoms. Patients
with response had a two years higher age (Mann Whitney P value
0.031) and a two months longer treatment period of the current
antipsychotic (Mann Whitney P value 0.039) than patients with-
out response. Haloperidol equivalents, duration of illness, DSM-
IV diagnoses and type of antipsychotic were not significantly dif-
ferent between response groups.
All polymorphisms were validated and had a missing genotype
rate below 10% in the total sample. No polymorphism deviated
from Hardy–Weinberg equilibrium. The allele and genotype fre-
quencies are shown in Table 2. Due to the low prevalence of scores
4, 5, 6 and 7 on the CGI-I, we used three ordinal groups of re-
sponse: a CGI-I score of 1, 2, and 3 or higher. Rs6314 and
rs1799732 showed too low cell counts when tested additive, and
were subsequently tested dominantly. The null hypothesis of par-
allel lines was not rejected for any of the polymorphisms tested.
In Table 3 the associations with response are depicted. Two
of the nine polymorphisms showed a significant association with
response on positive symptoms. The Gly (C) allele of Ser9Gly of
the DRD3 gene was associated with more improvement on posi-
tive symptoms (P value 0.034). The T-allele of 677-C/T of the
MTHFR gene also showed more improvement (P value 0.019).
Both results were in the same direction as the previous associa-
tion studies reporting on these polymorphisms (Staddon et al.,
2002; Szekeres et al., 2004; Scharfetter et al., 1999; Joober et
al., 2000a). The Gly-allele and T-allele showed odds ratios of
1.39 (95% CI 1.03–1.90) and 1.45 (95% CI 1.06–1.98) for being
in a better response category, respectively.
4. Discussion
In this study we aimed to replicate previously reported sig-
nificant findings from candidate gene studies on positive
symptoms improvement in patients with psychotic disorders
treated with antipsychotics. Of the nine tested polymor-
phisms two were tested significantly: Ser9Gly of the DRD3
gene and 677-C/T of the MTHFR gene.
Previous positive association studies with Ser9Gly of DRD3
in Caucasian patients were performed in prospective studies
with patients using clozapine (Scharfetter et al., 1999), olanza-
pine (Staddon et al., 2002), and several SGA (Szekeres et al.,
2004). In all three studies the Gly allele was associated with
better response. All three studies used different symptom
scales and treatment duration varied between 12 weeks and
6 months. Three other studies (two clozapine and one FGA)
with Caucasian patients showed no significant association
Table 1 Descriptive statistics of 329 Caucasian patients using antipsychotics, stratified by improvement on positive symptoms.
Improvement (n=247) No improvement (n=82) P-value
Age (years), median (range) 27 (16–47) 25 (16–42) 0.031
Gender (male) 197 (80%) 63 (77%) 0.52
Duration of illness (years), median (range) 3.4 (0.2–21.4) 3.2 (0.2–12.0) 0.99
Duration of current treatment (months), median (range) 4 (1–60) 6 (1–110) 0.039
Current dose (haloperidol equivalents a), median (range) 4.8 (0.6–18.2) 6.6 (0.6–21.0) 0.33
DSM-IV diagnosis 0.45
Schizophrenia 163 (66%) 57 (70%)
Schizo-affective disorder 37 (15%) 9 (11%)
Schizophreniform disorder 6 (2%) 3 (4%)
Psychotic disorder NOS 28 (11%) 9 (11%)
Delusional disorder 6 (2%) 4 (5%)
Other 7 (3%) 0 (0%)
Antipsychotic 0.24
Risperidone 55 (22%) 20 (24%)
Olanzapine 68 (28%) 12 (15%)
Quetiapine 14 (6%) 4 (5%)
Clozapine 22 (9%) 8 (10%)
Haloperidol 19 (8%) 5 (6%)
Aripiprazole 2 (1%) 3 (4%)
Other 16 (7%) 6 (7%)
Multiple antipsychotics 25 (10%) 12 (15%)
Missing 26 (11%) 12 (15%)
a Calculated as outlined by Andreasen et al. (2010).
628 J. Vehof et al.(Joober et al., 2000b; Malhotra et al., 1998; Shaikh et al.,
1996). In vitro studies indicate that the Gly variant is associated
with higher dopamine binding affinity (Lundstrom and Turpin,
1996). However, the biological function is hard to interpret
since the Gly variant was mostly associated with poor response
in Chinese populations (Reynolds et al., 2005; Lane et al.,
2005). This different direction of association with response
may be explained by a linkage disequilibrium status with anoth-
er functional polymorphism.
Only one study has been performed regarding 677-C/T of
MTHFR and antipsychotic response (Joober et al., 2000a).
The T allele was found more often in responders compared
to non-responders, all having FGA. The 677-C/T polymorphismTable 2 Frequencies of alleles and genotypes of polymorphisms
disorder.
Gene rs-id Chromosome
position
Variant
name
A
DRD2 rs1800497 Chr11:113270827 Taql_A C
rs1799732 Chri11:113346252 -141C C
DRD3 rs6280 Chr3:113890814 Ser9Gly T
HTR2A rs6314 Chr13:47409033 His452Tyr C
rs6311 Chrl3:47471477 102-T/C C
HTR2C rs3813929 X:113818519 -759C_T C
rs6318 X:113965734 Cys23Ser G
COMT rs4680 Chr22:19951270 Val158Met A
MTHFR rs1801133 Chrl:11856378 677-C/T C
a Major allele given first.
b MAF = minor allele frequency.
c Carriers of variant allele, polymorphism positioned on X-chromosomis functional (Frosst et al., 1995) and is possibly associated
with risk of schizophrenia itself (Shi et al., 2008; Allen et
al., 2008). MTHFR is required for the synthesis of 5-
methyltetrahydrofolate, the primary circulatory form of
folate and the carbon donor for homocysteine remethylation
to methionine. Homozygous individuals (TT) have around one
third of the expected MTHFR enzyme activity, and heterozy-
gotes (CT) have around two third activity, compared to the
most common genotype CC (Frosst et al., 1995). Some patients
with homocysteinuria, an inborn error of metabolism that can
be caused by rare and severe mutations in the MTHFR gene,
have exhibited schizophrenia-like symptoms (Freeman et al.,
1975). Furthermore, high levels of homocysteine have beenin 329 Caucasian patients with a non-affective psychotic
lleles a MAF b Genotypes
11 12 22
/T 0.17 228 (69%) 89 (27%) 12 (4%)
/Del 0.11 262 (80%) 60 (18%) 5 (2%)
/C 0.32 150 (46%) 139 (43%) 36 (11%)
/T 0.1 255 (80%) 59 (19%) 3 (1%)
/T 0.45 92 (28%) 177(54%) 59 (18%)
/T 0.18 244 (83%) – 49 (17%) c
/C 0.16 249 (84%) – 48 (16%) c
/G 0.46 91 (28%) 169 (52%) 68 (21%)
/T 0.32 153 (47%) 141 (43%) 35 (11%)
e.
Table 3 Results of association analyses between polymorphisms and clinical improvement on positive symptoms in 329
Caucasian patients with a non-affective psychotic disorder.
Ordinal regression a
Gene rs-id Variant name Alleles b Beta Odds ratio P-value
DRD2 rs1800497 TaqI_A C/T −0.24 0.79 0.21
rs1799732 -141C C/Del −0.36 0.70 0.17
DRD3 rs6280 Ser9Gly T/C −0.33 0.72 0.034
HTR2A rs6314 His452Tyr C/T −0.17 0.84 0.53
rs6311 T102C C/T 0.10 1.11 0.53
HTR2C c rs3813929 -759C_T C/T 0.08 1.08 0.79
rs6318 Cys23Ser G/C −0.47 0.63 0.13
COMT rs4680 Val158Met A/G 0.08 1.08 0.62
MTHFR rs1801133 677-C/T C/T −0.37 0.69 0.019
a Ordinal regression analysis with CGI-I improvement as dependent variable, and the number of minor alleles (0, 1 or 2) of the poly-
morphism as independent variable (additive model), corrected for age and gender. A negative beta or odds ratiob1 means more im-
provement (lower CGI score) per extra minor allele. Significant results (pb0.05) are shown in bold.
b Major allele given first.
c Polymorphisms tested in a dominant model.
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eral reports link a high plasma level of homocysteine to various
neurological conditions also, such as pregnancies complicated
by neural tube defects (Bakker and Brandjes, 1997) and
migraine (Oterino et al., 2010). Together with the association
we replicated, this points out that MTHFR may be involved in
the interaction with antipsychotic medication.
In this study we did not replicate seven of the previously
associated polymorphisms with response on positive symp-
toms. When a more conservative correction for multiple
testing was applied, such as Bonferroni, even the two repli-
cations would not be significant. An important question
regards the explanation of our findings. A likely explanation
for the variation in results from pharmacogenetic studies is
the heterogeneity in the definition and characterization of
the phenotype as well as in the characterization of the
genetic variability. This concerns the present study as well.
An important difference of our study from other studies is
the time between start of the medication and assessment
of improvement. The time of assessment is variable in our
study, because we measured CGI-I cross-sectionally in our
cohort. However, since most patients show response in the
first month after the start of an antipsychotic (Derks et al.,
2010) we consider our method valid for pharmacogenetic
purposes. We have a relatively big group of patients showing
improvement, what can be expected when response is cross-
sectionally measured. Patients who do not respond well are
less likely to continue an antipsychotic and will eventually
switch to another antipsychotic. This might have underesti-
mated the results, because we have a smaller range of
response outcome. In addition, due to the cross-sectional
nature of our study we had to use a relatively generic mea-
sure, in this case the CGI-I, to assess response to antipsy-
chotics. This approach might be responsible for a relatively
imprecise measurement of the true response. To perform a
true replication study, all methodologies and patient char-
acteristics should be identical. This is however not possible
when testing different polymorphisms at once, all tested
before in different studies with different approaches. Anoth-
er difference between pharmacogenetic studies on antipsy-
chotics (including ours) is the inclusion of all antipsychoticsas opposed to focusing on a single antipsychotic. Different
drug types, treatment duration and response assessment
methods may significantly alter study results (Arranz et al.,
2000b). We believe that this is a fairly homogeneous group
of patients, all with a non-affective psychotic disorder. How-
ever, it might very well be possible that pharmacogenetic
associations still differ between the diagnoses we included.
Of course publication bias might be an important contribut-
ing factor as well, i.e. positive results have a better chance
of being published than negative results. A combination of
above mentioned aspects is probably the reason why most
pharmacogenetic association results regarding response on
antipsychotics are conflicting: positive associations are often
not replicated. Apart from the limitations of the cross-
sectional design we used, our study has also several strengths.
Compared to most other candidate studies we have a relative-
ly large sample size of more than 300 patients using antipsy-
chotics. Our study does not suffer from heterogeneity with
regard to ethnicity as we have a homogeneous group of Cauca-
sian patients of Northern European ancestry.
In conclusion, two of the previously reported associations
between polymorphisms and treatment response were repli-
cated in the present study. Heterogeneity in patient samples
and outcome variables as well as publication bias may all
play a role in lack of replication, found in our study, as in
others. The direction of the associations presented here in
DRD3 (Ser9Gly) and MTHFR (677-C/T) is in line with previous
association studies in Caucasian patients. These polymor-
phisms may be of clinical value if their added value to
other clinical predictors of response can be demonstrated
in future research.
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